. Author manuscript; available in PMC: 2016 Jan 27.

Published in final edited form as: Mol Cancer Ther. 2013 Jan 3;12(3):255–263. doi: 10.1158/1535-7163.MCT-12-0777

Table 1. Summary of 2-ME2 and 2-ME2-PD1 pharmacokinetic parameters.

Sprague Dawley rats were implanted with carotid artery, and jugular and/or femoral vein catheters. The Culex Automated Pharmacology System facilitated pharmacokinetic analysis of the resulting plasma concentration-time data was performed using PK Solutions software.

	2-ME2	2-ME2-PD1
Route	Intravenous	Intravenous	Oral	Oral
Dose (mg/kg)	5.21	10	20	31.5
Corrected Dose (mg/kg)	5.21	6.06	12.13	19.11
AUC_t-480 (ng•min•mL^-1)	19253	4967	2006	3516
C_max (ng/mL)	1221	121	8.4	9.9
T_1/2 (min)	59	262	807	411
Bioavailability¹ (%)	100	21.8	4.4	4.9

Bioavailability values are through 480 minutes